BSH 2022 | Selecting the best treatment option in CLL
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, Sutton, UK, discusses treatment selection for patients with chronic lymphocytic leukemia (CLL). As more treatment options are becoming available to patients, treatment choice is based on both the efficacy and toxicity of a drug, and whether a patient has low-risk or high-risk prognostic features. For example, while a patient with low-risk disease may be treated with a fixed-duration venetoclax-based regimen, a patient with high-risk disease will be treated with continuous therapy. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honoraria: Abbvie; AstraZeneca; Gilead, Janssen; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kirin
